Boston Scientific just announced it received FDA approval for the SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES). This is the first BP-DES stent to be available in the U.S. to treat coronary artery disease.
The stent’s coating, as well as the polymer that controls the release of the embedded drug, are completely absorbed by the body. This takes about three months to complete, with the vessel ending up completely free of the polymer and the drug coating.
The absorption of the drug coating is “synchronized” with the breakdown of the polymer, helping to alleviate known side effects from extended exposure to permanent polymers.
The result is a bare stent remaining in the vessel while most of the scarring prevented.
The system has had European approval since 2012.
Source: Boston Scientific